missing translation for 'onlineSavingsMsg'
Learn More

Invitrogen™ CD39 Biosimilar Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Marca:  Invitrogen™ MA558491

 Ver más versiones de este producto

Código de producto. 30283940

  • 500.00€ / 100 microgramos

Por favor, para comprar este producto. ¿No tiene usuario web? Regístrese hoy mismo.

Este artículo no se puede devolver. Vea la política de devoluciones

Descripción

Descripción

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °. This antibody can also be cross referenced by the term TTX-030.

CD39 cell surface antigen is a 70-100kD molecule expressed on peripheral blood B cells, monocytes, T cell clones, and also weakly expressed on granulocytes. CD39 has intrinsic ecto-ATPase activity. Expression of CD39 is induced on T cells and increased on B cells as a late activation antigen.
TRUSTED_SUSTAINABILITY
Especificaciones

Especificaciones

CD39 Biosimilar
Recombinant Monoclonal
Unconjugated
Human
100 μg
Primary
-20°C, Avoid Freeze/Thaw Cycles
Lyophilized
ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance
1 mg/mL
25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2
Protein A
RUO
Human
Antibody
IgG4
Sugerencias de productos

Sugerencias de productos

Videos
SDS
Documentos

Documentos

Certificados
Promociones

Promociones

Corrección del contenido de un producto

Proporcione sus comentarios sobre el contenido del producto rellenando el siguiente formulario.

Título del producto

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.